Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Modulation of Hyperandrogenic Anovulation Through Fenugreek Seeds

22. maj 2026 opdateret af: Maria Aslam, University of Lahore

Modulation of Hyperandrogenic Anovulation Through Fenugreek(Trigonella Foenum Graecum L.) Seeds Among Young Females

Hyperandrogenic anovulation is a common gynecological illness that impacts the ovaries, vagina and uterus. According to Statistics, in Pakistan 17.6% of individuals seeking treatment at infertility clinics were found to be affected by hyperandrogenic anovulation. Studies indicate that fenugreek seeds have the potential to improve insulin sensitivity, control hormone levels, namely the increased androgens linked to hyperandrogenic anovulation, and promote ovulation, a process commonly interrupted in individuals with hyperandrogenic anovulation. In order to create a therapy plan that is both affordable and easily accessible for women who suffer from hyperandrogenic anovulation, this study aims to determine the therapeutic efficacy of fenugreek seed powder in reducing symptoms related to the illness. Furthermore, it aims to increase knowledge on the extensive utilization of fenugreek seed powder as a natural treatment for hyperandrogenic anovulation.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

  • To collect data, written consent was obtained from the hospital and university administration.

  • After receiving signed informed consent, the data were collected.

    1. Screening: The participants who meet the study inclusion criteria were enrolled and FSH/LH, Insulin resistance or lipid profile samples were taken by the hospital lab assistant. The participants will be requested not to alter their routine physical activity.
    2. Allocation: Following screening, participants were divided evenly into three groups: experimental group (1, 2) and one control group. The participants received different dosage in different experimental groups of fenugreek seeds powder) c.Follow up: A systematic communication plan will be developed in order to follow up with participants on their daily consumption of the suggested fenugreek powder through telephonic conversations. For continuous assistance there was a WhatsApp group set up where members may ask issues and get help associated with hyperandrogenic anovulation. The follow up for patients were conducted every month; baseline and after 60 days. Appointments for follow-up exams were made in order to track developments, anthropometric measurements were calculated every follow up and modify the dosage as necessary. The baseline and post study test were compared to test the hypothesis.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

70

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Pakistan
      • Lahore, Pakistan, 54000
        • Punjab medical center, jail road, Lahore

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Female have been BMI more than 25
  • Patients with irregular periods or hormonal imbalance
  • Patients with age 15 to 25 years of young females

Exclusion Criteria:

  • Pregnant & Lactating Women
  • Any history of allergic reaction to fenugreek seeds
  • Severe gastrointestinal disorders like crohn's disease
  • People with liver or kidney issue

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Control group
• Control group (G0): Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast prescribed by doctor.
Medicin: Control
Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast for the duration of 02 months.
Eksperimentel: fenugreek seeds low dose
3gram/ half teaspoon fenugreek seeds powder
Kosttilskud: Fenugreek seeds (G1):
Participants were advised to take 3g/half teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 month.
Eksperimentel: Fenugreek seeds high dose
6gram/ one teaspoon fenugreek seeds
Kosttilskud: Fenugreek seeds (G2)
Participants were advised to take 6g/one teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 months.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
FSH/LH Test
Tidsramme: 2 months
Ratio of Follicle Stimulating Hormone (FSH) to Luteinizing Hormone (LH)
2 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University of Lahore

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. september 2024

Primær færdiggørelse (Faktiske)

11. november 2024

Studieafslutning (Faktiske)

11. december 2024

Datoer for studieregistrering

Først indsendt

31. juli 2025

Først indsendt, der opfyldte QC-kriterier

8. maj 2026

Først opslået (Faktiske)

14. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • IRB-UOL-FAHS/930/2023

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Control

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Qatar

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner